Literature DB >> 11248073

Intralymphatic immunization enhances DNA vaccination.

K J Maloy1, I Erdmann, V Basch, S Sierro, T A Kramps, R M Zinkernagel, S Oehen, T M Kündig.   

Abstract

Although DNA vaccines have been shown to elicit potent immune responses in animal models, initial clinical trials in humans have been disappointing, highlighting a need to optimize their immunogenicity. Naked DNA vaccines are usually administered either i.m. or intradermally. The current study shows that immunization with naked DNA by direct injection into a peripheral lymph node enhances immunogenicity by 100- to 1,000-fold, inducing strong and biologically relevant CD8(+) cytotoxic T lymphocyte responses. Because injection directly into a lymph node is a rapid and easy procedure in humans, these results have important clinical implications for DNA vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248073      PMCID: PMC30648          DOI: 10.1073/pnas.051630798

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA.

Authors:  S Oehen; T Junt; C López-Macías; T A Kramps
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

2.  Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease.

Authors:  M Schulz; P Aichele; M Vollenweider; F W Bobe; F Cardinaux; H Hengartner; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1989-09       Impact factor: 5.532

Review 3.  Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity.

Authors:  R M Zinkernagel; S Ehl; P Aichele; S Oehen; T Kündig; H Hengartner
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

4.  Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

Authors:  J D Boyer; K E Ugen; B Wang; M Agadjanyan; L Gilbert; M L Bagarazzi; M Chattergoon; P Frost; A Javadian; W V Williams; Y Refaeli; R B Ciccarelli; D McCallus; L Coney; D B Weiner
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

5.  DNA vaccination against persistent viral infection.

Authors:  L P Martins; L L Lau; M S Asano; R Ahmed
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

6.  Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity.

Authors:  J B Ulmer; R R Deck; C M DeWitt; T M Fu; J J Donnelly; M J Caulfield; M A Liu
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

7.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

8.  DNA-based immunization against hepatitis B virus.

Authors:  H L Davis; C L Brazolot Millan
Journal:  Springer Semin Immunopathol       Date:  1997

9.  Naive and memory T cells show distinct pathways of lymphocyte recirculation.

Authors:  C R Mackay; W L Marston; L Dudler
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D.

Authors:  R M Zinkernagel; T Leist; H Hengartner; A Althage
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  40 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Detailed analysis of the CD8+ T-cell response following adenovirus vaccination.

Authors:  Teng Chih Yang; Kelley Dayball; Yong Hong Wan; Jonathan Bramson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model.

Authors:  Arne Dietrich; Christoph Stockmar; Gabriela Aust; Susan Endesfelder; Anke Guetz; Ulrich Sack; Manfred Schoenfelder; Johann Hauss
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-04       Impact factor: 4.553

Review 4.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

5.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

Review 6.  Engineering New Approaches to Cancer Vaccines.

Authors:  Naveen K Mehta; Kelly D Moynihan; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2015-07-08       Impact factor: 11.151

Review 7.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

8.  Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration.

Authors:  Xi Zhan; Kenny K Tran; Hong Shen
Journal:  Mol Pharm       Date:  2012-11-20       Impact factor: 4.939

Review 9.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

10.  Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Authors:  Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.